Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients

American Journal of Health-System Pharmacy

Volumn 70, Issue 17, 2013, Pages 1507-1512

  Heavner, Mojdeh S ^a   Tichy, Eric M ^b   Yazdi, Marina ^c   Formica, Richard N ^d   Kulkarni, Sanjay ^e   Emre, Sukru ^f  

^a Department of Pharmacy   (United States)

^b Solid Organ Transplantation   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

^d Temple University School of Medicine   (United States)

^e Department of Medicine and Surgery   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS; GENERIC DRUG; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BIOPSY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; BLOOD; GRAFT REJECTION; MEDICINAL CHEMISTRY; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; DRUGS, GENERIC; FEMALE; GRAFT REJECTION; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899035649     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120783     Document Type: Article

References (28)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004; 4:378-83.
2. Pirsch JD, Miller J, Deierhoi MH et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997; 63:977-83.
3. Vincenti F, Jensik SC, Filo RS et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002; 73:775-82.
4. Mendez R, Gonwa T, Yang HC et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation. 2005; 80:303-9.
5. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2011 annual data report. Rockville, MD: Department of Health and Human Services; 2012.
6. Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data. Br J Med. 2005; 331:810-21.
7. Momper JD, Ridenour TA, Schonder KS et al. The impact of conversion from Prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant. 2011; 11:1861-7.
8. McDevitt-Potter LM, Sadaka B, Tichy EM et al. A multicenter experience with generic tacrolimus conversion. Transplantation. 2011; 92:653-7.
9. Spence MM, Nguyen LM, Chan J. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Pharmacotherapy. 2012; 32:981-7.
10. Johnston A, Holt DW. Immunosuppressant drugs - the role of therapeutic monitoring. Br J Clin Pharmacol. 2001; 52(suppl 1):61S-73S.
11. Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentrationclinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998; 44:381-7.
12. Dantal J, Hourmant M, Cantrovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporine regimens. Lancet. 1998; 351:623-8.
13. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357:2562-75.
14. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9(suppl 3):S19-20.
15. Roza A, Tomlanovich S, Merion R et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation. 2002; 74:1013-7.
16. Taber DJ, Baillie GM, Ascraft EE et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation. 2005; 80:1633-5.
17. Qazi YA, Forrest A, Tornatore K et al. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant. 2006; 20:313-7.
18. Sabatini S, Ferguson RM, Helderman JH et al. Drug substitution in transplantation: a National Kidney Foundation white paper. Am J Kidney Dis. 1999; 33:389-97.
19. Alloway RR, Isaacs R, Lake K et al. Report of the American Society of Transplantation Conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant. 2003; 3:1211-5.
20. Uber PA, Ross HJ, Zuckermann AO et al. Generic drug immunosuppression in thoracic transplantation. J Heart Lung Transplant. 2009; 28:655-60.
21. Alloway RR, Sadaka B, Trofe-Clark J et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant. 2012; 12:2825-31.
22. Mardigyan V, Giannetti N, Cecere R et al. Best single time points to predict the area-under-the-time-curve in long-term heart transplant patients taking mycophenolate in combination with cyclosporine or tacrolimus. J Heart Lung Transplant. 2005; 24:1614-8.
23. Keown P, Landsberg D, Halloran P et al. A randomized prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Transplantation. 1998; 66:1744-52.
24. Cantarovich M, Barkun JS, Tchervenkov JI et al. Comparison of Neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation. 1998; 66:1621-7.
25. Cantarovich M, Bessner JG, Barkun JS et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant. 1998; 12:243-9.
26. De Jonge H, Naesens M, Kuypers RJ. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit. 2009; 31:416-35.
27. Red Book Online System [intranet database]. Version 5.1. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.; 2011.
28. Food and Drug Administration. Tacrolimus. Orange book: approved drug products with therapeutic equivalence evaluations. www.accessdata.fda.gov/scripts/cder/ob (accessed 2012 Dec 28).